Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232973 | 1.00 | BCL9 (0.57) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL125510 | 0.93 | HTR2A (0.56) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL10062010 | 0.93 | HTR2A (0.56) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL2597400 | 0.91 | BCL9 (0.63) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL18699060 | 0.90 | BCL9 (0.55) | BCL9CTNNB1HTR2AMGLLGAA | |
| Hydrochloric Acid SCHEMBL30544551 | 0.90 | BCL9 (0.61) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL23044637 | 0.89 | HTR2A (0.53) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL1104745 | 0.89 | HTR2A (0.53) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL12082016 | 0.89 | HTR2A (0.53) | BCL9CTNNB1HTR2AMGLLGAA | |
| SCHEMBL30233044 | 0.89 | HTR2A (0.53) | BCL9CTNNB1HTR2AMGLLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801686-B | Insulin-oligomer conjugates, formulations and uses thereof | 比奥孔有限公司 | 2020-04-07 | — | — | CN | disclosed |
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| EP-1773878-B1 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| US-8563685-B2 | Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| EP-1773878-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | Nobex Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014673-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | NOBEX CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | NOBEX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | GPR119, INSR, IAPP | BCL9 4443/4885CTNNB1 4357/4885HTR2A 3089/4885 |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | FABP2, SLC27A1, SLC27A2 | BCL9 817/4885CTNNB1 4561/4885HTR2A 3254/4885 |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | FABP2, SLC27A1, SLC27A2 | BCL9 844/4885CTNNB1 4581/4885HTR2A 3259/4885 |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | INSR, GPR119, IAPP | BCL9 3751/4885CTNNB1 4883/4885HTR2A 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.